Report cover image

Lexicon Pharmaceuticals Inc (LXRX) - Financial and Strategic SWOT Analysis Review

Publisher GlobalData
Published Jul 29, 2025
Length 52 Pages
SKU # GBDT20284396

Description

Lexicon Pharmaceuticals Inc (LXRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Lexicon Pharmaceuticals Inc (Lexicon) is a biopharmaceutical company, which focuses on the discovery, development and commercialization of innovative treatments for human diseases. Lexicon is focusing on the introduction of its approved medication, Inpefa (sotagliflozin), into the market specifically for the treatment of heart failure. The company has advanced multiple drug candidates into clinical development and has clinical-stage drug program sotagliflozin for hypertrophic cardiomyopathy (HCM) and type 1 diabetes. Its clinical and preclinical development programs, LX9211, are meant for the treatment of diabetes and neuropathic pain, respectively. It has business collaborations with several pharmaceutical and biotechnology companies. The company operates an office in New Jersey and has a laboratory in Texas. Lexicon is headquartered at The Woodlands, Texas, the US.

Lexicon Pharmaceuticals Inc Key Recent Developments

Apr 02,2025: Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
Mar 28,2025: Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug
Mar 06,2025: Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Jan 21,2025: Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Some sections may be missing if data is unavailable for the company

Table of Contents

52 Pages
Section 1 - About the Company
Lexicon Pharmaceuticals Inc - Key Facts
Lexicon Pharmaceuticals Inc - Key Employees
Lexicon Pharmaceuticals Inc - Key Employee Biographies
Lexicon Pharmaceuticals Inc - Major Products and Services
Lexicon Pharmaceuticals Inc - History
Lexicon Pharmaceuticals Inc - Company Statement
Lexicon Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Lexicon Pharmaceuticals Inc - Business Description
R&D Overview
Lexicon Pharmaceuticals Inc - Corporate Strategy
Lexicon Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Lexicon Pharmaceuticals Inc - Strengths
Lexicon Pharmaceuticals Inc - Weaknesses
Lexicon Pharmaceuticals Inc - Opportunities
Lexicon Pharmaceuticals Inc - Threats
Lexicon Pharmaceuticals Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
Lexicon Pharmaceuticals Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 02, 2025: Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
Mar 28, 2025: Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug
Mar 06, 2025: Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Jan 21, 2025: Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain
Jan 02, 2025: Lexicon Appoints Scott Coiante as Chief Financial Officer
Nov 25, 2024: Lexicon Pharmaceuticals to Participate in December Investor Conferences
Nov 20, 2024: Lexicon Appoints Ivan H. Cheung to Board of Directors
Oct 17, 2024: Lexicon partners Viatris for global expansion of sotagliflozin
Sep 16, 2024: Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer
Aug 13, 2024: Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Lexicon Pharmaceuticals Inc, Key Facts
Lexicon Pharmaceuticals Inc, Key Employees
Lexicon Pharmaceuticals Inc, Key Employee Biographies
Lexicon Pharmaceuticals Inc, Major Products and Services
Lexicon Pharmaceuticals Inc, History
Lexicon Pharmaceuticals Inc, Subsidiaries
Lexicon Pharmaceuticals Inc, Key Competitors
Lexicon Pharmaceuticals Inc, Ratios based on current share price
Lexicon Pharmaceuticals Inc, Annual Ratios
Lexicon Pharmaceuticals Inc, Annual Ratios (Cont...1)
Lexicon Pharmaceuticals Inc, Annual Ratios (Cont...2)
Lexicon Pharmaceuticals Inc, Interim Ratios
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
Lexicon Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Lexicon Pharmaceuticals Inc, Performance Chart (2020 - 2024)
Lexicon Pharmaceuticals Inc, Ratio Charts
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025

Search Inside Report

How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.